TSE.4540
Supplementary Materials
The Fiscal Year Ended March 31, 2023
May 9, 2023
TSUMURA & CO.
Consolidated Statements of Income ・・・・・ | 1 | |
Investments, R&D expenses, etc. ・・・・・ | 1 | |
Product sales | ・・・・・ | 2 |
Growth rates of 129 prescription Kampo products ・・・・・ | 2 | |
Consolidated Balance Sheets | ・・・・・ | 3 |
Consolidated Statements of Cash Flows ・・・・・ | 3 | |
Quarterly data | ||
Consolidated Statements of Income ・・・・・ | 4 | |
Consolidated Balance Sheets | ・・・・・ | 4 |
Consolidated Statements of Cash Flows ・・・・・ | 5 | |
Product sales | ・・・・・ | 5 |
Consolidated Statements of Income | (Million yen) | |||||||||||||||||
FY 3/2022 | FY 3/2023 | Year-on-year | Plan | Vs.planned | Full-year forecast for FY 3/2024 | |||||||||||||
Year-on- | Year-on- | |||||||||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | Amount | % | Amount | % of sales | |||||||
year | year | |||||||||||||||||
(Amount) | (%) | |||||||||||||||||
Net sales | 129,546 | 100.0% | 140,043 | 100.0% | 10,497 | 8.1% | 138,500 | 100.0% | 1,543 | 101.1% | Net sales | 150,500 | 100.0% | 10,456 | 7.5% | |||
Domestic | 119,567 | 92.3% | 124,684 | 89.0% | 5,116 | 4.3% | 124,200 | 89.7% | 484 | 100.4% | Domestic business | 133,300 | 88.6% | 8,601 | 6.9% | |||
Overseas | 9,978 | 7.7% | 15,359 | 11.0% | 5,380 | 53.9% | 14,300 | 10.3% | 1,059 | 107.4% | China business | 17,200 | 11.4% | 1,854 | 12.1% | |||
Cost of sales | 63,081 | 48.7% | 71,762 | 51.2% | 8,680 | 13.8% | 69,800 | 50.4% | 1,962 | 102.8% | Cost of sales | 83,000 | 55.1% | 11,237 | 15.7% | |||
Gross profit on sales | 66,465 | 51.3% | 68,281 | 48.8% | 1,816 | 2.7% | 68,700 | 49.6% | (418) | 99.4% | Gross profit on sales | 67,500 | 44.9% | (781) | (1.1)% | |||
Selling, general and | 44,088 | 34.0% | 47,365 | 33.8% | 3,277 | 7.4% | 47,900 | 34.6% | (534) | 98.9% | Selling, general and | 49,500 | 32.9% | 2,134 | 4.5% | |||
administrative expenses | administrative expenses | |||||||||||||||||
Operating profit | 18,000 | 12.0% | (2,916) | (13.9)% | ||||||||||||||
Operating profit | 22,376 | 17.3% | 20,916 | 14.9% | (1,460) | (6.5)% | 20,800 | 15.0% | 116 | 100.6% | ||||||||
Domestic business | 18,400 | ー | (2,790) | (13.2)% | ||||||||||||||
China business | (400) | ー | (126) | ー | ||||||||||||||
Ordinary profit | 25,904 | 20.0% | 23,453 | 16.7% | (2,451) | (9.5)% | 21,200 | 15.3% | 2,253 | 110.6% | Ordinary profit | 18,600 | 12.4% | (4,853) | (20.7)% | |||
Profit attributable to owners | 18,836 | 14.5% | 16,482 | 11.7% | (2,354) | (12.5)% | 15,000 | 10.8% | 1,482 | 109.9% | Profit attributable to owners | 13,000 | 8.6% | (3,482) | (21.1)% | |||
of parent | of parent | |||||||||||||||||
Investments, R&D expenses, etc. | (Million yen) | |||||||||||||||||
FY 3/2022 | FY 3/2023 | Year-on-year | Plan | Vs.planned | Full-year forecast for FY 3/2024 | |||||||||||||
Year-on- | Year-on- | |||||||||||||||||
Amount | % of sales | Amount | % of sales | Amount | % | Amount | % of sales | Amount | % | Amount | % of sales | |||||||
year | year | |||||||||||||||||
(Amount) | (%) | |||||||||||||||||
Investments | 12,095 | 9.3% | 14,679 | 10.5% | 2,584 | 21.4% | 22,000 | 15.9% | (7,320) | 66.7% | Investments | 33,500 | 22.3% | 18,820 | 128.2% | |||
Capital investments | 11,456 | 8.8% | 11,172 | 8.0% | (284) | (2.5)% | 17,500 | 12.6% | (6,327) | 63.8% | Capital investments | 29,500 | 19.6% | 18,327 | 164.0% | |||
R&D expenses | 7,313 | 5.6% | 7,594 | 5.4% | 281 | 3.8% | 7,600 | 5.5% | (5) | 99.9% | R&D expenses | 8,500 | 5.6% | 905 | 11.9% | |||
Advertising expenses | 1,104 | 0.9% | 1,026 | 0.7% | (78) | (7.1)% | 1,000 | 0.7% | 26 | 102.6% | Advertising expenses | 1,000 | 0.7% | (26) | (2.6)% | |||
Depreciation | 8,743 | 6.7% | 10,101 | 7.2% | 1,358 | 15.5% | 9,800 | 7.1% | 301 | 103.1% | Depreciation | 10,200 | 6.8% | 98 | 1.0% | |||
Personnel expenses | 32,902 | 25.4% | 34,244 | 24.5% | 1,342 | 4.1% | 34,800 | 25.1% | (555) | 98.4% | Personnel expenses | 36,800 | 24.5% | 2,555 | 7.5% | |||
※From the current consolidated fiscal year, the "acquisition of property, plant and equipment" has been changed to "investment amount of property, plant and equipment and software, etc." and the comparative figures have been rearranged.
1
Product sales | (Million yen) | ||||||
Year-on- | Year-on- | ||||||
Rank | No. | 処方名 | FY 3/2022 | FY 3/2023 | year | year | |
(Amount) | (%) | ||||||
1 | ☆ | 100 | Daikenchuto | 9,569 | 9,739 | 169 | 1.8% |
2 | G | 41 | Hochuekkito | 7,232 | 7,727 | 494 | 6.8% |
3 | ☆ | 54 | Yokukansan | 7,379 | 7,380 | 1 | 0.0% |
4 | ☆ | 43 | Rikkunshito | 7,231 | 7,300 | 69 | 1.0% |
5 | G | 17 | Goreisan | 5,298 | 6,208 | 910 | 17.2% |
6 | G | 24 | Kamishoyosan | 4,833 | 5,050 | 217 | 4.5% |
7 | 68 | Shakuyakukanzoto | 4,763 | 4,893 | 130 | 2.7% | |
8 | ☆ | 107 | Goshajinkigan | 3,509 | 3,421 | (87) | (2.5)% |
9 | 114 | Saireito | 3,264 | 3,277 | 12 | 0.4% | |
10 | 29 | Bakumondoto | 3,258 | 3,236 | (21) | (0.7)% | |
17 | G | 108 | Ningin'yoeito | 1,936 | 2,128 | 191 | 9.9% |
18 | G | 137 | Kamikihito | 1,722 | 2,067 | 344 | 20.0% |
24 | ☆ | 14 | Hangeshashinto | 1,358 | 1,390 | 32 | 2.4% |
Total of "Drug Fostering" Program formulations | 29,048 | 29,233 | 184 | 0.6% | |||
Total of Growing formulations | 21,023 | 23,182 | 2,159 | 10.3% | |||
Total of 129 prescription Kampo products | 114,165 | 119,362 | 5,197 | 4.6% | |||
☆ | :"Drug Fostering" Program formulations |
- :Growing formulations
Growth rates of 129 prescription Kampo products
FY 3/2023 | FY 3/2023 | FY 3/2023 | FY 3/2023 | |||||
FY 3/2019 | FY 3/2020 | FY 3/2021 | FY 3/2022 | 2Q | 3Q | 4Q | ||
1Q | cumulative | cumulative | cumulative | |||||
Amount | 2.7% | 1.8% | 1.1% | 8.1% | 6.7% | 6.8% | 5.3% | 4.6% |
Number of items with higher yen sales | 83 | 66 | 82 | 110 | 101 | 106 | 99 | 98 |
2
Consolidated Balance Sheets | (Million yen) | |||
As of March 31, | As of | March 31, | Increase / | |
2022 | 2023 | decrease | ||
Total assets | 350,981 | 396,813 | 45,831 | |
Current assets | 229,420 | 268,320 | 38,900 | |
Liquid assets | 122,431 | 152,839 | 30,408 | |
Inventories | 92,751 | 101,726 | 8,974 | |
Non-current assets | 121,561 | 128,492 | 6,931 | |
Property, plant and equipment | 90,040 | 93,415 | 3,375 | |
Total liabilities | 92,871 | 124,566 | 31,695 | |
Current liabilities | 45,875 | 47,205 | 1,329 | |
Non-current liabilities | 46,996 | 77,361 | 30,365 | |
Total net assets | 258,109 | 272,246 | 14,136 | |
Consolidated Statements of Cash Flows | (Million yen) | |||
As of March 31, | As of | March 31, | Increase / | |
2022 | 2023 | decrease | ||
Cash flows from operating activities | 21,314 | 16,452 | (4,861) | |
Cash flows from investing activities | (9,111) | (15,493) | (6,382) | |
Cash flows from financing activities | (8,181) | 24,423 | 32,604 | |
Cash and cash equivalents at the end of the quarter | 67,536 | 94,730 | 27,194 | |
3
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Tsumura & Co. published this content on 09 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 May 2023 07:39:05 UTC.